Long-term results of a double perfusion schedule using high dose hyperthermia and melphalan sequentially in extensive melanoma of the lower limb

Melanoma Research

Volumn 13, Issue 4, 2003, Pages 395-399

  Noorda, Eva M ^a   Vrouenraets, Bart C ^a   Nieweg, Omgo E ^a   Klaase, Joost M ^b   Van Der Zee, Jacoba ^c   Kroon, Bin B R ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Drug toxicity; Induced hyperthermia; Melanoma; Regional perfusion

Indexed keywords

ANTINEOPLASTIC AGENT; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLISTER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; EDEMA; ERYTHEMA; FEMALE; HUMAN; HYPERTHERMIA; HYPERTHERMIC THERAPY; ISOLATED LIMB PERFUSION; LEG; MALE; MELANOMA; PRIORITY JOURNAL; REGIONAL PERFUSION; SKIN TUMOR; TISSUE REACTION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; LOWER EXTREMITY; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0042367516     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200308000-00009     Document Type: Article

References (34)

1. Vrouenraets BC, Nieweg OE, Kroon BBR. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 1996; 83:1319-1328.
2. Klaase JM, Kroon BB, van Geel AN, Eggermont AM, Franklin HR, van Dongen JA. Is there an indication for a double perfusion schedule with melphalan for patients with recurrent melanoma of the limbs? Melanoma Res 1994; 4 (suppl 1):13-16.
3. Klaase JM, Kroon BB, van Geel AN, Eggermont AM, Franklin HR, van Dongen JA. A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer 1993; 71:2990-2994.
4. Klaase JM, Kroon BB, Eggermont AM, van Geel AN, Schraffordt Koops H, Oldhoff J, et al. A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities. Eur J Cancer 1995; 31A:58-63.
5. Cavaliere R, Ciocatto EC, Giovanella BC, Heidelberger C, Johnson RO, Margottini M, et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 1967; 20:1351-1381.
6. Vaglini M, Ammatuna M, Nava M, Prada A, Rovini D, Santinami M, Cascinelli N. Regional perfusion at high temperature in treatment of stage IIIA-IIIAB melanoma patients. Tumori 1983; 69:585-588.
7. Di Filippo F, Calabro A, Giannarelli D, Carlini S, Cavaliere F, Moscarelli F, Cavaliere R. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 1989; 63:2551-2561.
8. Storm FK, Morton DL. Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am J Surg 1985; 150:32-35.
9. Bryant PJ, Balderson GA, Mead P, Egerton WS. Hyperthermic isolated limb perfusion for malignant melanoma: response and survival. World J Surg 1995; 19:363-368.
10. Santinami M, Belli F, Cascinelli N, Rovini D, Vaglini M. Seven years' experience with hyperthermic perfusions in extracorporeal circulation for melanoma of the extremities. J Surg Oncol 1989; 42:201-208.
11. Vaglini M, Andreola S, Attili A, Belli F, Marolda R, Nava M, et al. Hyperthermic antiblastic perfusion in the treatment of cancer of the extremities. Tumori 1985; 71:355-359.
12. Kroon BBR, Klaase JM, van Geel AN, Eggermont AMM. Application of hyperthermia in regional isolated perfusion for melanoma of the limbs. Reg Cancer Treat 1992; 4:223-226.
13. van der Zee J, Kroon BB, Nieweg OE, van de Merwe SA, Kampinga HH. Rationale for different approaches to combined melphalan and hyperthermia in regional isolated perfusion. Eur J Cancer 1997; 33:1546-1550.
14. van de Merwe SA, van den Berg AP, Kroon BB, van den Berge AW, Klaase JM, van der Zee J. Modification of human tumour and normal tissue pH during hyperthermic and normothermic antiblastic regional isolation perfusion for malignant melanoma: a pilot study. Int J Hyperthermia 1993; 9:205-217.
15. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989; 49:4373-4384.
16. Lyons JC, Kim GE, Song CW. Modification of intracellular pH and thermosensitivity. Radiat Res 1992; 129:79-87.
17. van der Zee J, Broekmeyer-Reurink MP, van den Berg AP, van Geel BN, Jansen RF, Kroon BB, et al. Temperature distribution and pH changes during hyperthermic regional isolation perfusion. Eur J Cancer Clin Oncol 1989; 25:1157-1163.
18. Jansen RF, van Geel BN, van der Zee J, Hagenbeek A, Levendag PC. Intractable cutaneous non-Hodgkin's lymphoma of the lower limb. Complete remission after sequential regional isolated hyperthermic perfusion and perfusion with /-phenylalanine-mustard (melphalan, L-Pam). Cancer 1989; 64:392-395.
19. Kroon B, Klaase J, van de Merwe SA, van Dongen J, van der Zee J. Results of a double perfusion schedule using high-dose hyperthermia and melphalan sequentially for recurrent melanoma of the limbs: a pilot study. Reg Cancer Treat 1992; 4:305-308.
20. Wieberdink J, Benckhuijsen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18:905-910.
21. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: WHO, 1979.
22. Streffer C. Molecular and cellular mechanisms of hyperthermia. In: Seegenschmiedt M, Fessenden P, Vernon CC (editors). Thermoradiotherapy and Thermochemotherapy. Berlin, Springer-Verlag, 1995; pp. 47-74.
23. Field SB, Morris CC. The relationship between heating time and temperature: its relevance to clinical hyperthermia. Radiother Oncol 1983; 1:179-186.
24. Gerweck LE. Modification of cell lethality at elevated temperatures. The pH effect. Radiat Res 1977; 70:224-235.
25. Fraker DL. What is the best regional therapy? Melanoma Res 1997; 7 (suppl 1):S42.
26. Liénard D, Eggermont A, Schraffordt Koops H, Kroon BBR, Towse G, Hiemstra S, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999; 9:491-502.
27. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996; 14:479-489.
28. Feldman AL, Alexander HR Jr, Bartlett DL, Fraker DL, Libutti SK. Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma. Ann Surg Oncol 1999; 6:562-567.
29. Lingam MK, Byrne DS, Aitchison T, MacKie RM, McKay AJ. A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb. Eur J Cancer 1996; 32A:1668-1673.
30. Klaase JM, Kroon B, van Geel AN, van Wijk J, Franklin HR, Eggermont A, Hart A. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg 1994; 178:564-572.
31. Vrouenraets BC, Kroon B, Klaase JM, Nieweg OE, van Slooten GW, van Dongen JA. Severe acute regional toxicity after normothermic or 'mild' hyperthermic isolated limb perfusion with melphalan for melanoma. Melanoma Res 1995; 5:425-431.
32. Krementz ET, Sutherland CM, Muchmore JH. Isolated hyperthermia chemotherapy perfusion for limb melanoma. Surg Clin North Am 1996; 76:1313-1330.
33. Liénard D, Eggermont A, Schraffordt Koops H, Kroon B, Rosenkaimer F, Autier P, Lejeune FJ. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res 1994; 4 (suppl 1):21-26.
34. Fraker D, Alexander H, Ross M, Bartlett D, Tyler D, Libutti LS, et al. A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon gamma. Society of Surgical Oncology 55th Annual Cancer Symposium 2002; S8.